Avitas Wealth Management LLC Sells 357 Shares of Johnson & Johnson (NYSE:JNJ)

Avitas Wealth Management LLC trimmed its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 1.0% in the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 35,031 shares of the company’s stock after selling 357 shares during the quarter. Johnson & Johnson comprises approximately 1.3% of Avitas Wealth Management LLC’s portfolio, making the stock its 19th biggest position. Avitas Wealth Management LLC’s holdings in Johnson & Johnson were worth $6,188,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the business. Vanguard Group Inc. increased its holdings in Johnson & Johnson by 1.2% in the 3rd quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock worth $40,078,885,000 after buying an additional 2,815,655 shares in the last quarter. State Street Corp increased its holdings in Johnson & Johnson by 0.6% in the 3rd quarter. State Street Corp now owns 141,886,311 shares of the company’s stock worth $23,178,548,000 after buying an additional 803,013 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Johnson & Johnson by 3.3% in the 3rd quarter. Price T Rowe Associates Inc. MD now owns 25,428,626 shares of the company’s stock worth $4,154,022,000 after buying an additional 805,831 shares in the last quarter. Legal & General Group Plc boosted its position in Johnson & Johnson by 2.3% in the second quarter. Legal & General Group Plc now owns 18,839,914 shares of the company’s stock worth $3,344,295,000 after purchasing an additional 421,779 shares during the last quarter. Finally, FMR LLC boosted its position in Johnson & Johnson by 20.8% in the second quarter. FMR LLC now owns 18,725,049 shares of the company’s stock worth $3,323,883,000 after purchasing an additional 3,229,032 shares during the last quarter. 67.94% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Down 1.1 %

NYSE JNJ opened at $152.38 on Friday. The stock’s 50 day moving average is $161.97 and its 200 day moving average is $167.91. The company has a current ratio of 0.99, a quick ratio of 0.77 and a debt-to-equity ratio of 0.35. Johnson & Johnson has a 12 month low of $150.71 and a 12 month high of $186.69. The stock has a market cap of $396.84 billion, a PE ratio of 22.61, a P/E/G ratio of 2.65 and a beta of 0.54.

Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 EPS for the quarter, topping analysts’ consensus estimates of $2.22 by $0.13. Johnson & Johnson had a return on equity of 35.76% and a net margin of 18.90%. The company had revenue of $23.71 billion for the quarter, compared to analysts’ expectations of $23.90 billion. During the same period in the previous year, the firm earned $2.13 EPS. The firm’s revenue was down 4.4% compared to the same quarter last year. Research analysts predict that Johnson & Johnson will post 10.5 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st were issued a $1.13 dividend. The ex-dividend date of this dividend was Friday, February 17th. This represents a $4.52 dividend on an annualized basis and a yield of 2.97%. Johnson & Johnson’s dividend payout ratio is presently 67.06%.

Insider Buying and Selling

In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of Johnson & Johnson stock in a transaction that occurred on Monday, March 6th. The stock was sold at an average price of $154.66, for a total value of $164,248.92. Following the sale, the insider now owns 9,215 shares of the company’s stock, valued at approximately $1,425,191.90. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 0.35% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on JNJ. Guggenheim began coverage on Johnson & Johnson in a research report on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 target price on the stock. Piper Sandler dropped their target price on Johnson & Johnson from $55.00 to $52.00 in a research report on Monday, February 6th. Morgan Stanley raised their target price on Johnson & Johnson from $176.00 to $180.00 and gave the stock an “equal weight” rating in a research report on Wednesday, January 25th. StockNews.com began coverage on Johnson & Johnson in a research report on Thursday. They issued a “strong-buy” rating on the stock. Finally, Atlantic Securities raised their target price on Johnson & Johnson from $160.00 to $168.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 25th. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $174.73.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.